php-banner-video.jpg

UP-TO-DATE, RESEARCH BASED INFORMATION ABOUT PSYCHEDELICS.

Emerging Research Emerging Research

The association between diverse psychological protocols and the efficacy of psilocybin-assisted therapy for clinical depressive symptoms: a Bayesian meta-analysis

Compared with manualized nondirective psychological support, the other three psychological approaches did not differ significantly. The improvement of depressive symptoms was not associated with the psychological protocols in adult patients receiving psilocybin-assisted therapy.

Read More
Emerging Research Emerging Research

Adverse events in studies of classic psychedelics: A systematic review and meta-analysis

Reports of serious AEs (SAEs) and nonserious AEs (NSAEs) requiring medical or psychiatric attention in classic psychedelic research were rare. In this systematic review and meta-analysis of 3504 participants from 114 studies, SAEs were reported for no healthy participants and approximately 4% of participants with preexisting neuropsychiatric disorders; however, for most studies, there was concern for underdetection or incomplete AE reporting.

Read More
Emerging Research Emerging Research

National Institutes of Health awards $2.4 million grant to cross-disciplinary team of researchers to study psychedelics for methamphetamine addiction

The Louisiana Addiction Research Center at LSU Health Shreveport have been awarded a five-year, $2.4 million research grant from the National Institute on Drug Abuse (NIDA) to uncover critical insights into how psychedelics could be used as a therapeutic to treat methamphetamine addiction.

Read More
Emerging Research Emerging Research

Pharmacological and non-pharmacological predictors of the LSD experience in healthy participants

The pharmacodynamic effects of lysergic acid diethylamide (LSD) are diverse and different in different individuals. Effects of other psychoactive substances have been shown to be critically influenced by non-pharmacological factors such as personality traits and mood states. The aim of this study was to determine pharmacological and psychological predictors of the LSD effects in healthy human subjects.

Read More
Emerging Research Emerging Research

Comparative oral monotherapy of psilocybin, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, ayahuasca, and escitalopram for depressive symptoms: systematic review and Bayesian network meta-analysis

Of the available psychedelic treatments for depressive symptoms, patients treated with high dose psilocybin showed better responses than those treated with placebo in the antidepressant trials, but the effect size was small.

Read More
Emerging Research Emerging Research

MDMA plus exposure therapy for PTSD

MAPS have just given a grant of $200K to see if MDMA can enhance the effectiveness of Massed Exposure Therapy (MET). MET delivers 10 x 90min exposure therapy sessions over 10 days and has been shown to be pretty much as effective to the one 90min session per week for 10 weeks of standard Prolonged Exposure Therapy. As MAPS comment "This study is one of the first trials exploring whether psychedelic-assisted therapy can enhance an existing evidence-based PTSD therapeutic treatment."

Read More
Emerging Research Emerging Research

The FDA’s decision on MDMA-assisted psychotherapy: A call for pragmatism and scientific rigor

What is particularly surprising is the stark contrast between the FDA’s decision and the conclusions reached by the Dutch State Committee on MDMA. Based on the same body of evidence, the Dutch committee (consisting of scientists, psychiatrists, legal experts, drug prevention and harm reduction specialists) arrived at a radically different conclusion: MDMA-AT is promising, effective, relatively safe and warrants more scientific research to further explore its therapeutic potential.

Read More